Viking Therapeutics, Inc. (0VQA.L)
USD 39.07
(-17.95%)
USD 39.07
(-17.95%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 936 Thousand USD | -25.71% |
| 2022 | 1.26 Million USD | 0.0% |
| 2021 | - USD | -100.0% |
| 2020 | 29 Thousand USD | -91.94% |
| 2019 | 360 Thousand USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | -100.0% |
| 2015 | 2.15 Million USD | 70.2% |
| 2014 | 1.26 Million USD | 445.23% |
| 2013 | 231.85 Thousand USD | 442.34% |
| 2012 | 42.75 Thousand USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 755 Thousand USD | 0.0% |
| 2024 Q2 | 766 Thousand USD | 0.0% |
| 2024 Q1 | 852 Thousand USD | 0.0% |
| 2023 Q1 | 1.18 Million USD | -6.27% |
| 2023 Q3 | 1.01 Million USD | -7.45% |
| 2023 Q2 | 1.1 Million USD | -6.86% |
| 2023 Q4 | 936 Thousand USD | -8.06% |
| 2023 FY | 936 Thousand USD | -25.71% |
| 2022 Q2 | 1.41 Million USD | -5.1% |
| 2022 Q4 | 1.26 Million USD | -5.76% |
| 2022 Q3 | 1.33 Million USD | -5.45% |
| 2022 FY | 1.26 Million USD | 0.0% |
| 2022 Q1 | 1.49 Million USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 FY | - USD | -100.0% |
| 2021 Q1 | - USD | -100.0% |
| 2021 Q4 | - USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2020 FY | 29 Thousand USD | -91.94% |
| 2020 Q4 | 29 Thousand USD | -74.78% |
| 2020 Q1 | 279 Thousand USD | -22.5% |
| 2020 Q2 | 198 Thousand USD | -29.03% |
| 2020 Q3 | 115 Thousand USD | -41.92% |
| 2019 Q2 | 513 Thousand USD | -12.76% |
| 2019 Q4 | 360 Thousand USD | -17.81% |
| 2019 Q3 | 438 Thousand USD | -14.62% |
| 2019 Q1 | 588 Thousand USD | 0.0% |
| 2019 FY | 360 Thousand USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | -100.0% |
| 2017 Q1 | 3.71 Million USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2016 Q1 | 3.13 Million USD | 45.94% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | -100.0% |
| 2016 FY | - USD | -100.0% |
| 2015 Q1 | 1.42 Million USD | 13.12% |
| 2015 Q2 | - USD | -100.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | 2.15 Million USD | 0.0% |
| 2015 FY | 2.15 Million USD | 70.2% |
| 2014 Q1 | 237.19 Thousand USD | 2.3% |
| 2014 Q2 | 320.25 Thousand USD | 35.02% |
| 2014 FY | 1.26 Million USD | 445.23% |
| 2014 Q4 | 1.26 Million USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | 231.85 Thousand USD | 0.0% |
| 2013 Q3 | 231.85 Thousand USD | 0.0% |
| 2013 FY | 231.85 Thousand USD | 442.34% |
| 2012 FY | 42.75 Thousand USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 24.37 Million USD | 96.16% |
| Dynavax Technologies Corporation | 252.41 Million USD | 99.629% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 97.18% |
| Perrigo Company plc | 3.63 Billion USD | 99.974% |
| Illumina, Inc. | 1.48 Billion USD | 99.937% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.997% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | 6.4% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 99.988% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 99.993% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 99.461% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.965% |
| Unity Biotechnology, Inc. | 23.53 Million USD | 96.024% |
| Waters Corporation | 2.3 Billion USD | 99.959% |
| Biogen Inc. | 7.18 Billion USD | 99.987% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | 97.207% |
| Evolus, Inc. | 120.35 Million USD | 99.222% |
| Adicet Bio, Inc. | 17.7 Million USD | 94.713% |
| Cara Therapeutics, Inc. | 37.07 Million USD | 97.476% |
| bluebird bio, Inc. | 224.41 Million USD | 99.583% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 99.813% |
| FibroGen, Inc. | 89.69 Million USD | 98.956% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 99.966% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | 71.099% |
| Homology Medicines, Inc. | 43.17 Million USD | 97.832% |
| Geron Corporation | 35.05 Million USD | 97.33% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 99.96% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 99.759% |
| Myriad Genetics, Inc. | 130.9 Million USD | 99.285% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 99.033% |
| Zoetis Inc. | 6.56 Billion USD | 99.986% |
| Abeona Therapeutics Inc. | 4.4 Million USD | 78.737% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 99.953% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 99.842% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 99.871% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 97.262% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 99.933% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | 97.952% |
| Verastem, Inc. | 40.08 Million USD | 97.665% |
| Nektar Therapeutics | 112.62 Million USD | 99.169% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 99.474% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | 69.551% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 99.917% |
| OPKO Health, Inc. | 222.03 Million USD | 99.578% |
| Exelixis, Inc. | 189.94 Million USD | 99.507% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 99.638% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 130.06 Million USD | 99.28% |
| Imunon, Inc. | 1.13 Million USD | 17.844% |
| Blueprint Medicines Corporation | 610.96 Million USD | 99.847% |
| Insmed Incorporated | 1.19 Billion USD | 99.922% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 99.938% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 98.358% |
| TG Therapeutics, Inc. | 100.11 Million USD | 99.065% |
| Incyte Corporation | 29.16 Million USD | 96.79% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 99.79% |